Oxford Events, the new replacement for OxTalks, will launch on 16th March. From now until the launch of Oxford Events, new events cannot be published or edited on OxTalks while all existing records are migrated to the new platform. The existing OxTalks site will remain available to view during this period.
From 16th, Oxford Events will launch on a new website: events.ox.ac.uk, and event submissions will resume. You will need a Halo login to submit events. Full details are available on the Staff Gateway.
Louis-Eric Trudeau is currently full professor of pharmacology, physiology and neurosciences at the Université de Montréal Faculty of Medicine. He is also the director of the SNC, a campus-based neuroscience group at the Université de Montréal focusing on neural connectivity. He was previously trained in Montreal, Paris, France, and the United States. He has obtained numerous salary awards and research grants from the Canadian Institutes of Health Research, Neuroscience Canada, the Fonds de la Recherche en Santé du Québec, the EJLB Foundation, Brain Canada, the Krembil Foundation, The Michael J Fox Foundation for Parkinson’s research, Parkinson Society Canada and more recently the Aligning Science Across Parkinson’s (ASAP) initiative. He has published over 115 peer-reviewed articles. His main research interests concern the mechanisms that control neurotransmitter release, connectivity and vulnerability of dopamine-containing neurons in the brain and the causes of Parkinson’s disease. His laboratory has made numerous contributions to our understanding of the ability of dopamine neurons to use glutamate as a co-transmitter, on the functions of dopamine autoreceptors and more recently on the origin of the selective vulnerability of dopamine neurons in Parkinson’s disease and on the implication of autoimmune mechanisms in this disease. Much of his current research is aimed at identifying strategies to increase the resilience of dopamine neurons, to develop better animal models of Parkinson’s and to identify new therapeutic approaches for this neurodegenerative disease.